NIAID Taps SRI International for $100M Radiation Exposure Drug Dev’t Contract; Polly Chang Comments

HealthThe National Institute of Allergy and Infectious Diseases has awarded a division of SRI International a potential five-year, $100 million contract to develop therapies for radiation exposure.

SRI Biosciences will carry out preclinical testing, good manufacturing practice development, stability studies, human clinical trials and formulation development work for NIAID under the multi-year contract, SRI said Tuesday.

The division will also help the agency move drug candidates through the Food and Drug Administration’s approval process.

Polly Chang, senior director of molecular and genetic toxicology at SRI Biosciences, said it will leverage its experience in radiation biology research and drug development to support the project.

Video of the Day

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles

The Ultimate Guide to Winning Government Contracts Let us show you how top executives are winning so you can replicate it